Trial Profile

A phase 2 study of KSI-301 for treatment of Wet age related macular degeneration (wet AMD) in China

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 27 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jul 2023 Status changed from planning to withdrawn prior to enrolment due to adverse events, according to a Kodiak Sciences media release.
07 Jul 2020 According to a Kodiak Sciences media release, the company plans to hold an R&D webinar on July 27, 2020 to discuss the planned registrational studies for KSI-301.
05 Feb 2020 According to an Kodiak Sciences media release, later in 2020 the company plans to initiate four additional pivotal clinical studies of KSI-301 with the objective to file an initial BLA in 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com